公开(公告)号：US20170319570A1

公开(公告)日：2017-11-09

申请号：US15662165

申请日：2017-07-27

申请人： Joel Flaxman Kaye

发明人： Joel Flaxman Kaye

IPC分类号： A61K31/4704 ,  A61K45/06 ,  A61K31/225

CPC分类号： A61K31/4704 ,  A61K31/225 ,  A61K31/47 ,  A61K45/06 ,  A61K2300/00

摘要： This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject laquinimod as an add-on therapy to or in combination with DMF. This invention also provides a package comprising laquinimod and DMF for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with DMF in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides a pharmaceutical composition comprising laquinimod and DMF for use in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and DMF in the preparation of a combination for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome.

公开(公告)号：US20130259856A1

公开(公告)日：2013-10-03

申请号：US13800047

申请日：2013-03-13

申请人： Joel Flaxman Kaye

发明人： Joel Flaxman Kaye

IPC分类号： A61K31/4704 ,  A61K45/06 ,  A61K31/225

CPC分类号： A61K31/4704 ,  A61K31/225 ,  A61K31/47 ,  A61K45/06 ,  A61K2300/00

摘要： This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject laquinimod as an add-on therapy to or in combination with DMF. This invention also provides a package comprising laquinimod and DMF for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with DMF in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides a pharmaceutical composition comprising laquinimod and DMF for use in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and DMF in the preparation of a combination for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome.

摘要翻译： 本发明提供了治疗患有多发性硬化症或呈现临床分离综合征的受试者的方法，其包括向所述受试者施用作为与DMF结合使用的附加疗法的拉喹莫德。 本发明还提供包含拉喹莫德和DMF的包装，用于治疗患有多发性硬化症或呈现临床分离综合征的受试者。 本发明还提供了用作附加治疗或与DMF结合治疗患有多发性硬化症或呈现临床分离综合征的受试者的拉喹莫德。 本发明还提供了包含拉喹莫德和DMF的药物组合物，用于治疗患有多发性硬化症或呈现临床分离综合征的受试者。 本发明还提供了拉喹莫德和DMF在制备用于治疗患有多发性硬化症或呈现临床分离的综合征的受试者的组合中的用途。

公开(公告)号：US20160000774A1

公开(公告)日：2016-01-07

申请号：US14853826

申请日：2015-09-14

申请人： Joel Flaxman Kaye

发明人： Joel Flaxman Kaye

IPC分类号： A61K31/4704 ,  A61K45/06 ,  A61K31/225

CPC分类号： A61K31/4704 ,  A61K31/225 ,  A61K31/47 ,  A61K45/06 ,  A61K2300/00

摘要： This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject laquinimod as an add-on therapy to or in combination with DMF. This invention also provides a package comprising laquinimod and DMF for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with DMF in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides a pharmaceutical composition comprising laquinimod and DMF for use in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and DMF in the preparation of a combination for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome.

公开(公告)号：US20170333418A1

公开(公告)日：2017-11-23

申请号：US15665061

申请日：2017-07-31

申请人： Hussein Hallak ,  Nora Tarcic ,  Joel Flaxman Kaye

发明人： Hussein Hallak ,  Nora Tarcic ,  Joel Flaxman Kaye

IPC分类号： A61K31/47 ,  A61K47/02 ,  A61K45/06 ,  A61K31/4704 ,  A61K31/137 ,  A61K9/48 ,  A61K9/28 ,  A61K9/14 ,  A61K9/00 ,  A61K47/26 ,  A61J1/03

CPC分类号： A61K31/47 ,  A61J1/035 ,  A61K9/0053 ,  A61K9/14 ,  A61K9/28 ,  A61K9/48 ,  A61K31/137 ,  A61K31/4704 ,  A61K45/06 ,  A61K47/02 ,  A61K47/26 ,  A61K2300/00

摘要： This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject laquinimod as an add-on therapy to or in combination with fingolimod. This invention also provides a package and a pharmaceutical composition comprising laquinimod and fingolimod for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with fingolimod in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and fingolimod in the preparation of a combination for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome.

公开(公告)号：US20150037263A1

公开(公告)日：2015-02-05

申请号：US14520145

申请日：2014-10-21

申请人： Hussein Hallak ,  Nora Tarcic ,  Joel Flaxman Kaye

发明人： Hussein Hallak ,  Nora Tarcic ,  Joel Flaxman Kaye

IPC分类号： A61K31/47 ,  A61K45/06 ,  A61J1/03 ,  A61K31/137

CPC分类号： A61K31/47 ,  A61J1/035 ,  A61K9/0053 ,  A61K9/14 ,  A61K9/28 ,  A61K9/48 ,  A61K31/137 ,  A61K31/4704 ,  A61K45/06 ,  A61K47/02 ,  A61K47/26 ,  A61K2300/00

摘要： This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject laquinimod as an add-on therapy to or in combination with fingolimod. This invention also provides a package and a pharmaceutical composition comprising laquinimod and fingolimod for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with fingolimod in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and fingolimod in the preparation of a combination for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome.

摘要翻译： 本发明提供了治疗患有多发性硬化或呈现临床分离综合征的受试者的方法，其包括以与芬戈莫德组合的附加疗法给予所述受试者的拉喹莫德。 本发明还提供一种包含药物组合物，其包含拉喹莫德和芬戈莫德，用于治疗患有多发性硬化症或呈现临床分离综合征的受试者。 本发明还提供了用作附加疗法或与芬戈莫德组合用于治疗患有多发性硬化症或呈现临床孤立综合征的受试者的拉喹莫德。 本发明还提供了拉喹莫德和芬戈莫德在制备用于治疗患有多发性硬化症或呈现临床分离综合征的受试者的组合的用途。

公开(公告)号：US20170224675A1

公开(公告)日：2017-08-10

申请号：US15495406

申请日：2017-04-24

申请人： Joel Flaxman Kaye

发明人： Joel Flaxman Kaye

IPC分类号： A61K31/4704 ,  A61K31/225 ,  A61K45/06

CPC分类号： A61K31/4704 ,  A61K31/225 ,  A61K31/47 ,  A61K45/06 ,  A61K2300/00

摘要： This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject laquinimod as an add-on therapy to or in combination with DMF. This invention also provides a package comprising laquinimod and DMF for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with DMF in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides a pharmaceutical composition comprising laquinimod and DMF for use in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and DMF in the preparation of a combination for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome.

公开(公告)号：US20150119420A1

公开(公告)日：2015-04-30

申请号：US14589684

申请日：2015-01-05

申请人： Joel Flaxman Kaye

发明人： Joel Flaxman Kaye

IPC分类号： A61K31/47 ,  A61K45/06 ,  A61K31/225

CPC分类号： A61K31/4704 ,  A61K31/225 ,  A61K31/47 ,  A61K45/06 ,  A61K2300/00

摘要： This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject laquinimod as an add-on therapy to or in combination with DMF. This invention also provides a package comprising laquinimod and DMF for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with DMF in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides a pharmaceutical composition comprising laquinimod and DMF for use in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and DMF in the preparation of a combination for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome.

摘要翻译： 本发明提供了治疗患有多发性硬化症或呈现临床分离综合征的受试者的方法，其包括向所述受试者施用作为与DMF结合使用的附加疗法的拉喹莫德。 本发明还提供包含拉喹莫德和DMF的包装，用于治疗患有多发性硬化症或呈现临床分离综合征的受试者。 本发明还提供了用作附加治疗或与DMF结合治疗患有多发性硬化症或呈现临床分离综合征的受试者的拉喹莫德。 本发明还提供了包含拉喹莫德和DMF的药物组合物，用于治疗患有多发性硬化症或呈现临床分离综合征的受试者。 本发明还提供了拉喹莫德和DMF在制备用于治疗患有多发性硬化症或呈现临床分离的综合征的受试者的组合中的用途。